The FDA’s breakthrough therapy designation for GSK’227 underscores its potential to address the critical unmet needs of ...
Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...
GSK has gained US FDA breakthrough therapy designation for GSK'227 to treat adults with relapsed or refractory osteosarcoma.
GSK5764227 (HS-20093) is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.
After a heart attack, humans lose millions of heart muscle cells that cannot regrow, often leading to heart failure where the ...
UC San Diego Health one of a few health care systems on West Coast to offer new gene therapy for hemophilia B.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GSK5764227 (GSK’227) for the treatment of adult patients with relapsed or refractory (R/R) osteosarcoma who have ...
The FDA bestows a Breakthrough Therapy designation to GSK's antibody-drug conjugate, GSK5764227, for treating relapsed or refractory osteosarcoma.
The company said Monday that fosigotifator failed to outperform placebo in slowing the neurodegenerative disease, but is ...
Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback